Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Short Interest Up 13.5% in December

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 26,030,000 shares, an increase of 13.5% from the December 15th total of 22,940,000 shares. Based on an average daily volume of 2,170,000 shares, the days-to-cover ratio is presently 12.0 days.

Institutional Investors Weigh In On Lineage Cell Therapeutics

A number of institutional investors have recently made changes to their positions in LCTX. SG Americas Securities LLC boosted its holdings in Lineage Cell Therapeutics by 35.5% during the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after acquiring an additional 18,053 shares during the period. XTX Topco Ltd purchased a new stake in shares of Lineage Cell Therapeutics during the second quarter valued at approximately $61,000. GSA Capital Partners LLP bought a new position in shares of Lineage Cell Therapeutics in the third quarter worth approximately $84,000. Rhumbline Advisers increased its stake in shares of Lineage Cell Therapeutics by 15.1% in the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock worth $132,000 after buying an additional 17,411 shares during the period. Finally, Barclays PLC raised its holdings in Lineage Cell Therapeutics by 311.3% during the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock valued at $192,000 after buying an additional 159,924 shares during the last quarter. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Trading Up 2.8 %

NYSEAMERICAN LCTX opened at $0.59 on Monday. Lineage Cell Therapeutics has a twelve month low of $0.48 and a twelve month high of $1.61. The stock has a market cap of $129.47 million, a price-to-earnings ratio of -4.90 and a beta of 1.18.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on LCTX shares. D. Boral Capital reissued a “buy” rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a research report on Friday, January 3rd. Maxim Group decreased their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Friday, January 10th. Finally, HC Wainwright upped their price objective on shares of Lineage Cell Therapeutics from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $4.80.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.